Table III.
Reported outcomes from the included studies
| Study ID | Operative outcomes | Postoperative outcomes | Pathologic outcomes | Oncologic outcomes | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operative time | Blood loss | Conversion to laparotomy | Incision length | Additional trocar(s) | Ileostomy | Perioperative mortality | Perioperative complications | Hospital stay | Reoperation | Readmission | Pain score | Analgesics requirements | Bowel movement recovery | Diet build up | Harvested lymph nodes | Specimen length | PRM | DRM | CRM | CRM involvement | Mesorectal grade | R0 resection | Follow up period | OS | DFS | Recurrence | |
| 2021 Sirikurnpiboon [11] | + | + | – | – | – | – | – | + | + | – | – | + | – | + | – | + | – | – | + | + | + | – | – | + | + | - | |
| 2020 Jiang [13] | + | + | + | + | + | – | + | + | + | – | + | + | – | – | + | + | – | + | + | – | + | – | – | + | + | + | + |
| 2018 Tei [14] | + | + | + | – | + | – | + | + | + | + | – | – | – | – | – | + | – | + | + | – | + | – | – | + | + | + | + |
| 2018 Nerup [16] | + | + | + | – | – | – | + | + | + | – | + | – | – | – | – | + | + | – | + | + | – | + | – | + | – | – | - |
| 2015 Bulut [17] | + | + | + | + | – | + | – | + | + | + | + | + | + | – | – | + | + | – | + | + | – | + | + | + | – | – | - |
| 2013 Sourrouille [24] | + | + | + | – | + | + | + | + | + | + | – | + | + | – | + | + | – | – | – | – | – | + | – | – | – | – | - |
PRM – proximal resection margin, DRM – distal resection margin, CRM – circumferential resection margin, OS – overall survival, DFS – disease-free survival.